Usefulness of Antibodies to Oxidized Low-Density Lipoproteins as Predictors of Morbidity and Prognosis in Heart Failure Patients Aged ≥65 Years

• Published in: The American journal of cardiology Vol. 116; no. 9; pp. 1379 - 1384
• Main Authors: Charach, Gideon, MD, Michowitz, Yoav, MD, Rogowski, Ori, MD, Charach, Lior, BA, Argov, Ori, MD, George, Jacob, MD, Grosskopf, Itamar, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2015; Elsevier Limited
• Subjects: Academic Medical Centers; Aged; Aged, 80 and over; Antibodies - blood; Atherosclerosis; Biomarkers - blood; Blood platelets; Cardiovascular; Chronic Disease; Family medical history; Female; Follow-Up Studies; Free radicals; Glucose; Heart attacks; Heart failure; Heart Failure - diagnosis; Heart Failure - epidemiology; Heart Failure - mortality; Hospitalization; Hospitalization - statistics & numerical data; Humans; Immunoglobulins; Israel - epidemiology; Laboratories; Lipoproteins, LDL - blood; Low density lipoprotein; Male; Medical records; Morbidity; Mortality; Oxidative stress; Peptides; Phosphatase; Predictive Value of Tests; Prognosis; Proteins; Retrospective Studies; Sensitivity and Specificity; Severity of Illness Index; Survival Rate; Variables; Israel; Tel Aviv Israel
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2015.07.053

Elevated level of antibodies to oxidized low-density lipoproteins (OxLDL-Ab) was shown to reliably predict morbidity and mortality in patients with heart failure (HF). Two hundred and eleven patients aged ≥65 years treated at the Heart Failure Unit, Tel Aviv-Sourasky Medical Center, were included in this retrospective study. The end points were time to the first hospitalization (morbidity), all-cause mortality, and a combination of the two (composite outcome). HF duration ranged from 8 to 10.5 years. Mean follow-up was 5.2 ± 1.9 years. The mean number of clinical visits was 18.3 ± 2.4. Participants were divided according to OxLDL-Ab level. Group 1 had Ox LDL-Ab level <200 arbitrary U/ml. Group 2 had OxLDL-Ab level ≥200 arbitrary U/ml. The mean time to the first hospitalization was 25.8 ± 17.0 months. The mortality rate was 44.1%. Combined mortality and hospitalization rate was 58.8%. Adjusted hazard ratios of OxLDL-Ab for hospitalization were 3.16, p <0.001, 95% confidence interval 1.740 to 5.736 and for composite outcome 2.67, p <0.001, 95% confidence interval 1.580 to 4.518. In conclusion, OxLDL-Ab level was the best predictor for both hospitalization and composite outcome. It may, thus, serve as a useful clue for early and more accurate detection of poorly controlled HF and as a marker for imminent exacerbations of thereof.